SCHEMBL6100255

SCHEMBL6100255

Cc1cc(COc2cccc(N3CCNCC3)n2)cc(C)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.53
HTR2A P28223 2/20 0.53
HTR2B P41595 2/20 0.53
ADRB1 P08588 3/20 0.52
HTR3A P46098 2/20 0.52
CHRM4 P08173 1/20 0.52
HTR1A P08908 1/20 0.52
CHRM5 P08912 1/20 0.52
CHRM1 P11229 1/20 0.52
CHRM3 P20309 1/20 0.52
FPR3 P25089 1/20 0.52
HTR1D P28221 1/20 0.52
HTR1B P28222 1/20 0.52
HTR1E P28566 1/20 0.52
GPR183 P32249 1/20 0.52
HTR7 P34969 1/20 0.52
HRH1 P35367 1/20 0.52
DRD3 P35462 1/20 0.52
SIGMAR1 Q99720 1/20 0.52
GPR35 Q9HC97 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097031 0.89 HTR2C (0.53) HTR2CHTR2AHTR2BADRB1HTR3A
SCHEMBL3104344 0.84 HTR2C (0.57) HTR2CHTR2AHTR2BADRB1HTR3A
Hydrochloric Acid SCHEMBL31061265 0.83 HTR2C (0.58) HTR2CHTR2AHTR2BADRB1HTR3A
SCHEMBL30138420 0.82 HTR2C (0.55) HTR2CHTR2AHTR2BADRB1HTR3A
SCHEMBL6099835 0.82 HTR2C (0.55) HTR2CHTR2AHTR2BADRB1HTR3A
SCHEMBL3266629 0.80 HTR3A (0.54) HTR2CHTR2AHTR2BADRB1HTR3A
SCHEMBL6100222 0.79 HTR6 (0.58) HTR2CHTR2AHTR2BADRB1HTR3A
SCHEMBL29664303 0.79 HTR6 (0.58) HTR2CHTR2AHTR2BADRB1HTR3A
SCHEMBL24337897 0.78 HTR2A (0.52) HTR2CHTR2AHTR2BADRB1HTR3A
SCHEMBL29491527 0.78 HTR2A (0.52) HTR2CHTR2AHTR2BADRB1HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7009051-B2 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity PFIZER INC (US) 2006-03-07 US claimed
US-20040014769-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity PFIZER INC. 2004-01-22 US claimed
EP-1254905-B1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity PFIZER PROD INC (US) 2003-12-17 EP claimed
US-20030008880-A1 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity PFIZER INC. 2003-01-09 US claimed
EP-1254905-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity Pfizer Products Inc. (US) 2002-11-06 EP claimed
US-7009051-B2 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity PFIZER INC (US) 2006-03-07 US disclosed
US-20040014769-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity PFIZER INC. 2004-01-22 US disclosed
EP-1254905-B1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity PFIZER PROD INC (US) 2003-12-17 EP disclosed
US-20030008880-A1 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity PFIZER INC. 2003-01-09 US disclosed
EP-1254905-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity Pfizer Products Inc. (US) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014769-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity HTR7, HTR1A, HTR2C HTR2C 3/4885HTR2A 11/4885HTR2B 6/4885
US-20030008880-A1 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity HTR7, HTR1A, HTR2C HTR2C 3/4885HTR2A 11/4885HTR2B 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.